Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 254

The DOI matches its Crossref record; 75 of the 75 references it cites were found in a registry or an index.

A comprehensive review of methodologies and application to use the real-world data and analytics platform TriNetX

Open access
Ludwig, Ralf J., Anson, Matthew, Zirpel, Henner, Thaci, Diamant, Olbrich, Henning, Bieber, Katja, Kridin, Khalaf, Dempfle, Astrid, Curman, Philip, Zhao, Sizheng S., Alam, Uazman · 2025 · Frontiers in Pharmacology

Abstract

Randomized controlled trials (RCTs) are the gold standard for evaluating the efficacy and safety of both pharmacological and non-pharmacological interventions. However, while they are designed to control confounders and ensure internal validity, their usually stringent inclusion and exclusion criteria often limit the generalizability of findings to broader patient populations. Moreover, RCTs are resource-intensive, frequently underpowered to detect rare adverse events, and sometimes narrowly focused due to their highly controlled environments. In contrast, real-world data (RWD), typically derived from electronic health records (EHRs) and claims databases, offers a valuable counterpart for answering research questions that may be impractical to address through RCTs. Recognizing this, the US Food and Drug Administration (FDA) has increasingly relied on real-world evidence (RWE) from RWD to support regulatory decisions and post-market surveillance. Platforms like TriNetX, that leverage large-scale RWD, facilitate collaborations between academia, industry, and healthcare organizations, and constitute an in-depth tool for retrieval and analysis of RWD. TriNetX’s federated network architecture allows real-time, privacy-compliant data access, significantly enhancing the ability to conduct retrospective studies and refine clinical trial designs. With access to currently over 150 million EHRs, TriNetX has proven particularly effective in filling gaps left by RCTs, especially in the context of rare diseases, rare endpoints, and diverse patient populations. As the role of RWD in healthcare continues to expand, TriNetX stands out as a critical tool that complements traditional clinical trials, bridging the gap between controlled research environments and real-world practice. This review provides a comprehensive analysis of the methodologies and applications of the TriNetX platform, highlighting its potential contribution to advance patient care and outcomes.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3389/fphar.2025.1516126

Cites

75 of 75 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 75 references

Metadata

Authors
Ludwig, R. J., Anson, M., Zirpel, H., Thaci, D., Olbrich, H., Bieber, K., Kridin, K., Dempfle, A., Curman, P., Zhao, S. S., & Alam, U.
Venue
Frontiers in Pharmacology
Published
2025-03-10
Volume
16
Pages
1516126-1516126
ISSN
1663-9812 (ISSN-L)
OpenAlex
W4408273436
Cited by
254
References
75
FWCI
190.76
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: A comprehensive review of methodologies and application to use the real-world data and analytics platform TriNetX. https://app.cochat.ai/papers/10.3389/fphar.2025.1516126
The paper
Ludwig, R. J., Anson, M., Zirpel, H., Thaci, D., Olbrich, H., Bieber, K., Kridin, K., Dempfle, A., Curman, P., Zhao, S. S., & Alam, U. (2025). A comprehensive review of methodologies and application to use the real-world data and analytics platform TriNetX. Frontiers in Pharmacology. https://doi.org/10.3389/fphar.2025.1516126

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.